Ernexa Therapeutics Inc. (ERNA): Nasdaq/NYSE listing notice — Eterna receives Nasdaq delisting notice for audit committee non-compliance; director Fiore resigns

Ernexa Therapeutics Inc.

Nasdaq notified Eterna on Oct 3, 2023 that audit committee no longer meets minimum three-member/independence requirement after Binder and Wagner resignations.
Cure period: until earlier of next annual meeting or Aug 9, 2024; if meeting before Feb 5, 2024, compliance due by Feb 5, 2024.
Director Gregory Fiore resigned Oct 4, 2023; not due to any disagreement with the company.
Nasdaq closed prior deficiency on independent director/audit/comp committee rules following appointment of Dorothy Clarke on Aug 31 and Sep 26, 2023.
Company evaluating director candidates to regain compliance; listing continues under symbol ERNA on Nasdaq.

item 3.01 item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Gregory Fiore

Director

ERNA · Ernexa Therapeutics Inc.

Effective: 2023-10-04
Filed: October 5, 2023, 7:59 PM ET

O n October 4, 2023 Gregory Fiore resigned from the Company’s board of directors.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(c)(4)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: audit committee
Rules: 5605, 5605(c)(4)

Exact text from the filing

October 3, 2023, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (the “Nasdaq”) stating that, as a result of the previously disclosed resignations of Mr. Brant C. Binder and Dr. Richard W. Wagner from the Company’s board of directors and audit committee, the Company is no longer in compliance with Nasdaq Listing Rule 5605, which, in relevant part, requires the audit committee to consist of at least three members, each of whom must be an independent director under the Nasdaq Listing Rules

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gregory Fiore resigned as Director at Ernexa Therapeutics Inc..

Action: resigned
Role: Director

Exact text from the filing

O n October 4, 2023 Gregory Fiore resigned from the Company’s board of directors.

View on SEC.gov

Browse all listing & compliance notices →

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-047156

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.